Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ANS014004 + PLB1004 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ANS014004 | ANS 014004|ANS-014004 | MET Inhibitor 59 | ANS014004 is a small molecule MET inhibitor with activity against MET D1228A and Y1230H, which potentially inhibits tumor cell proliferation and tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): C145). | |
| PLB1004 | PLB 1004|PLB-1004 | EGFR Exon 20 Insertion Inhibitor 15 EGFR Inhibitor (Pan) 63 | PLB1004 is an EGFR inhibitor with activity against L858R, T790M, exon 19 deletions, and exon 20 insertion mutations, which potentially decreases tumor growth (Cancer Res (2023) 83 (8_Supplement): CT102). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07285148 | Phase Ib/II | ANS014004 + PLB1004 ANS014004 + Osimertinib | A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer | Not yet recruiting | USA | 0 |